+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fibrate Drugs Market by Drug Type, Application, Patient Demographics, Distribution Channel, Formulation, End User, Route Of Administration, Mode Of Purchase - Global Forecast 2025-2030- Product Image
Fibrate Drugs Market by Drug Type, Application, Patient Demographics, Distribution Channel, Formulation, End User, Route Of Administration, Mode Of Purchase - Global Forecast 2025-2030- Product Image
Sale

Fibrate Drugs Market by Drug Type, Application, Patient Demographics, Distribution Channel, Formulation, End User, Route Of Administration, Mode Of Purchase - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6016409
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Fibrate Drugs Market grew from USD 3.45 billion in 2023 to USD 3.72 billion in 2024. It is expected to continue growing at a CAGR of 7.05%, reaching USD 5.56 billion by 2030.

Fibrate drugs, specialized lipid-modifying agents, primarily function to reduce triglyceride levels and increase high-density lipoprotein (HDL) cholesterol in the bloodstream, ultimately aimed at mitigating cardiovascular risks. Their scope spans a significant role in the therapeutic landscape due to rising instances of lipid disorders and cardiovascular diseases worldwide. The necessity of fibrate drugs has been underpinned by increasing awareness and preventive measures against heart diseases, along with the aging global population, which is more susceptible to lipid imbalances. These drugs find primary applications in managing hyperlipidemia, often prescribed when statins are not tolerated or in cases of marked hypertriglyceridemia. The end-use scope predominantly includes healthcare settings, such as hospitals and clinics, in addition to home care under medical supervision. Key growth factors influencing the fibrates market include advancements in drug formulation, heightened focus on personalized medicine, and an expanding geriatric population. Potential opportunities lie in emerging markets where the burden of lifestyle-related diseases is escalating and a rising emphasis on preventive healthcare, suggesting strategic geographic expansions and partnerships could be beneficial. However, challenges such as side effects, regulatory hurdles, and competition from alternative lipid-modifying therapies like statins could hinder market growth. Litigation related to drug efficacy and safety concerns also poses significant limitations. Innovations could focus on enhancing drug efficacy and safety profiles through novel delivery systems or combination therapies, which would cater to unmet needs and improve patient compliance. The market's nature is competitive yet fragmented, characterized by key players pursuing aggressive R&D and promotional activities. To remain competitive, stakeholders should prioritize addressing safety concerns, embracing digital health solutions for patient management, and investing in research exploring fibrates' broader cardiovascular benefits.

Understanding Market Dynamics in the Fibrate Drugs Market

The Fibrate Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Surging cases of hyperlipidemia among adult and geriatric population
    • Expansion of pharmaceutical companies in emerging markets with untapped potential
    • Advancements in drug delivery systems enhancing the efficacy of fibrate drugs
    • Rise in healthcare expenditure and access to modern medical facilities
  • Market Restraints
    • High costs associated with research and development of new fibrate formulations and variants
  • Market Opportunities
    • Niche market for fibrate drugs targeting genetic disorders involving lipid metabolism
    • Opportunities in personalized medicine through fibrate drugs for customized patient treatment plans
    • Demand for fibrate drugs in veterinary medicine for treating hyperlipidemia in animals
  • Market Challenges
    • Strict regulatory guidelines impacting the approval process of fibrate drugs in different regions

Exploring Porter’s Five Forces for the Fibrate Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Fibrate Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Fibrate Drugs Market

External macro-environmental factors deeply influence the performance of the Fibrate Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Fibrate Drugs Market

The Fibrate Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Fibrate Drugs Market

The Fibrate Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Fibrate Drugs Market

The Fibrate Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fibrate Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Allergan plc, Amgen Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Limited, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Lupin Limited, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Limited, and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Fibrate Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Bezafibrate
    • Clofibrate
    • Fenofibrate
      • Generic Fenofibrate
    • Gemfibrozil
  • Application
    • Cardiovascular Diseases
    • Dyslipidemia
    • Hyperlipidemia
    • Hypertriglyceridemia
  • Patient Demographics
    • Adults
    • Elderly
    • Pediatric
  • Distribution Channel
    • Drug Stores
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Formulation
    • Capsules
    • Suspensions
    • Tablets
  • End User
    • Clinics
    • Homecare
    • Hospitals
  • Route Of Administration
    • Injectable
    • Oral
  • Mode Of Purchase
    • Over The Counter
    • Prescription Based
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surging cases of hyperlipidemia among adult and geriatric population
5.1.1.2. Expansion of pharmaceutical companies in emerging markets with untapped potential
5.1.1.3. Advancements in drug delivery systems enhancing the efficacy of fibrate drugs
5.1.1.4. Rise in healthcare expenditure and access to modern medical facilities
5.1.2. Restraints
5.1.2.1. High costs associated with research and development of new fibrate formulations and variants
5.1.3. Opportunities
5.1.3.1. Niche market for fibrate drugs targeting genetic disorders involving lipid metabolism
5.1.3.2. Opportunities in personalized medicine through fibrate drugs for customized patient treatment plans
5.1.3.3. Demand for fibrate drugs in veterinary medicine for treating hyperlipidemia in animals
5.1.4. Challenges
5.1.4.1. Strict regulatory guidelines impacting the approval process of fibrate drugs in different regions
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Fibrate Drugs Market, by Drug Type
6.1. Introduction
6.2. Bezafibrate
6.3. Clofibrate
6.4. Fenofibrate
6.4.1. Generic Fenofibrate
6.5. Gemfibrozil
7. Fibrate Drugs Market, by Application
7.1. Introduction
7.2. Cardiovascular Diseases
7.3. Dyslipidemia
7.4. Hyperlipidemia
7.5. Hypertriglyceridemia
8. Fibrate Drugs Market, by Patient Demographics
8.1. Introduction
8.2. Adults
8.3. Elderly
8.4. Pediatric
9. Fibrate Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Drug Stores
9.3. Hospital Pharmacies
9.4. Online Pharmacies
9.5. Retail Pharmacies
10. Fibrate Drugs Market, by Formulation
10.1. Introduction
10.2. Capsules
10.3. Suspensions
10.4. Tablets
11. Fibrate Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare
11.4. Hospitals
12. Fibrate Drugs Market, by Route Of Administration
12.1. Introduction
12.2. Injectable
12.3. Oral
13. Fibrate Drugs Market, by Mode Of Purchase
13.1. Introduction
13.2. Over The Counter
13.3. Prescription Based
14. Americas Fibrate Drugs Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Fibrate Drugs Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Fibrate Drugs Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2023
17.2. FPNV Positioning Matrix, 2023
17.3. Competitive Scenario Analysis
17.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. FIBRATE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. FIBRATE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL FIBRATE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL FIBRATE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 17. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 19. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
FIGURE 21. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 25. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. FIBRATE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 31. FIBRATE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. FIBRATE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL FIBRATE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FIBRATE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. FIBRATE DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FIBRATE DRUGS MARKET SIZE, BY BEZAFIBRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CLOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FIBRATE DRUGS MARKET SIZE, BY GENERIC FENOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FIBRATE DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL FIBRATE DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL FIBRATE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL FIBRATE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL FIBRATE DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PRESCRIPTION BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 70. CANADA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. CANADA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 72. CANADA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 74. CANADA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. CANADA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 76. CANADA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. CANADA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. MEXICO FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. MEXICO FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. MEXICO FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 117. CHINA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. CHINA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 119. CHINA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. CHINA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 121. CHINA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. CHINA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 123. CHINA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. CHINA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. CHINA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 126. INDIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. INDIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 128. INDIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. INDIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 130. INDIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. INDIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 132. INDIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. INDIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. INDIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. INDONESIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 144. JAPAN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. JAPAN FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 146. JAPAN FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. JAPAN FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 148. JAPAN FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. JAPAN FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. JAPAN FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. JAPAN FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. JAPAN FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 159. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 186. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 195. TAIWAN FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. TAIWAN FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. TAIWAN FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 198. THAILAND FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 199. THAILAND FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 200. THAILAND FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. THAILAND FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 202. THAILAND FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. THAILAND FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 204. THAILAND FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. THAILAND FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. THAILAND FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 213. VIETNAM FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. VIETNAM FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. VIETNAM FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 226. DENMARK FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 227. DENMARK FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 228. DENMARK FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. DENMARK FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 230. DENMARK FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. DENMARK FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 232. DENMARK FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. DENMARK FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. DENMARK FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 235. EGYPT FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 236. EGYPT FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 237. EGYPT FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. EGYPT FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 239. EGYPT FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. EGYPT FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 241. EGYPT FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. EGYPT FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. EGYPT FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 244. FINLAND FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 245. FINLAND FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 246. FINLAND FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. FINLAND FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 248. FINLAND FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. FINLAND FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 250. FINLAND FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. FINLAND FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. FINLAND FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 253. FRANCE FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 254. FRANCE FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 255. FRANCE FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. FRANCE FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 257. FRANCE FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. FRANCE FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 259. FRANCE FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. FRANCE FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. FRANCE FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 262. GERMANY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 263. GERMANY FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 264. GERMANY FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. GERMANY FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 266. GERMANY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. GERMANY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 268. GERMANY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. GERMANY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. GERMANY FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. ISRAEL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. ISRAEL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 280. ITALY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 281. ITALY FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 282. ITALY FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. ITALY FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 284. ITALY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. ITALY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 286. ITALY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. ITALY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. ITALY FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 307. NORWAY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 308. NORWAY FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 309. NORWAY FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 310. NORWAY FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 311. NORWAY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. NORWAY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 313. NORWAY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. NORWAY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. NORWAY FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 316. POLAND FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 317. POLAND FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 318. POLAND FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 319. POLAND FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 320. POLAND FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. POLAND FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 322. POLAND FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. POLAND FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. POLAND FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 325. QATAR FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 326. QATAR FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 327. QATAR FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 328. QATAR FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 329. QATAR FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. QATAR FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 331. QATAR FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. QATAR FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. QATAR FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 334. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 335. RUSSIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 336. RUSSIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 337. RUSSIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 338. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 339. RUSSIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 340. RUSSIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. RUSSIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 342. RUSSIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 344. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 345. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 346. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 347. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 348. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 349. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 350. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 351. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 352. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 353. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 354. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 355. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 356. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 357. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 358. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 359. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 360. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 361. SPAIN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 362. SPAIN FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
TABLE 363. SPAIN FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 364. SPAIN FIBRATE

Companies Mentioned

The leading players in the Fibrate Drugs Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • Zydus Cadila

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.72 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.56 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Fibrate Drugs Market by Drug Type, by Product Type, by Distribution Channel, and By Region - Product Image

Fibrate Drugs Market by Drug Type, by Product Type, by Distribution Channel, and By Region

  • Report
  • 200 Pages
  • Global
From
Fibrate Drugs Global Market Report 2024 - Product Image

Fibrate Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Argentina Cholesterol Lowering Drug Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032 - Product Image

Argentina Cholesterol Lowering Drug Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

  • Report
  • 80 Pages
  • Argentina
From
Brazil Cholesterol Lowering Drug Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032 - Product Image

Brazil Cholesterol Lowering Drug Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

  • Report
  • 80 Pages
  • Brazil
From
Japan Lipid Lowering Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F - Product Image

Japan Lipid Lowering Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F

  • Report
  • 80 Pages
  • Japan
From

About the Fibrates Market

Fibrates are a class of drugs used to treat cardiovascular diseases, such as high cholesterol and triglyceride levels. They work by increasing the activity of the enzyme lipoprotein lipase, which helps to break down fats in the blood. Fibrates are often used in combination with statins, another class of drugs used to lower cholesterol levels. Fibrates are generally well tolerated, but can cause side effects such as muscle pain, nausea, and abdominal pain. Fibrates are available in both prescription and over-the-counter forms. Commonly prescribed fibrates include fenofibrate, gemfibrozil, and clofibrate. Over-the-counter fibrates include omega-3 fatty acids, which are found in fish oil supplements. Several companies are involved in the fibrates market, including Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.